Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

How to Manage Polymyalgia Rheumatica

  |  Issue: December 2015  |  

“However, the guidelines also acknowledge that individual dose-tapering schedules are needed and that there is no ‘one size fits all’ dose in management of this condition,” he adds.

Mary Beth Nierengarten is a freelance medical journalist based in St. Paul, Minn.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica. Arthritis Rheumatol. 2015 Oct;67(10):2569–2580.
  2. ACR releases new publications focused on polymyalgia rheumatica and gout [news release]. Atlanta: American College of Rheumatology. 2015 Sep 10.
  3. Dasgupta B, Hutchings A, Matteson EL. Polymyalgia rheumatica: The mess we are now in and what we need to do about it. Arthritis Rheum. 2006 Aug 15;55(4):518–520.
  4. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594–1597.
  5. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484–492.
  6. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2012 Apr;64(4):943–954.

Related Articles

    New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica

    The ACR has published three documents intended to provide clarity and consensus on management of osteoarthritis, classification criteria for Sjögren’s syndrome, and classification criteria for polymyalgia rheumatica. The documents, which represent the most current clinical evidence, research, and expert panel input and review, can help inform clinical practice and provide clearer target populations for future research.

    Permanent Vision Loss in Late Giant Cell Arteritis

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…